insulin detemir (Levemir) Report issue

Biologics Recombinant protein Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Insulin detemir, a long-acting human insulin analog, is sold under the brand name LEVEMIR to improve glycemic control in adults and children with diabetes mellitus. Insulin detemir binds to the insulin receptor. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. The primary activity of insulin detemir is the regulation of glucose metabolism. Insulin detemir crosses the BBB and reduces food intake, it improves weight management by an enhanced and prolonged centrally mediated reduction of energy intake.   NCATS

Chemistry

  • SMILES: CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc4ccccc4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@H](Cc6ccc(O)cc6)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc7ccc(O)cc7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]8CSSC[C@H](NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc9c[nH]cn9)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc%10ccccc%10)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc%11c[nH]cn%11)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc%12ccc(O)cc%12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N5)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N8)C(=O)N[C@@H](CC(=O)N)C(=O)O)[C@@H](C)O)C(=O)O
  • InChIKey: UGOZVNFCFYTPAZ-IOXYNQHNSA-N
  • Mol. Mass: 5916.93
  • ALogP: Missing data
  • ChEMBL Molecule:
    insulin detemir  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$20.9273 - $29.5762

Australia

$51.3559
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

detemir | ins levemir | insulin detemir | insulin,detemir,human | insulin detemir [rdna origin] | insulin detemir recombinant | insuline detemir | insulin levemir | levemir | levemir flexpen | levemir innolet | levemir penfill | nn304 | nn 304 | nn-304

Organizations (69)

Research & Development (69)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (3)


 

Diabetes Mellitus

Diabetes Mellitus, Type 1

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Alzheimer Disease (Phase 2)

Arteriosclerosis (Phase 4)

Atherosclerosis (Phase 4)

Auditory Diseases, Central (Phase 4)

Cardiovascular Diseases (Phase 4)

Cognitive Dysfunction (Phase 2)

Coronary Disease (Phase 3)

Cystic Fibrosis (Phase 3)

Diabetes, Gestational (Phase 3)

Diabetes Mellitus ()

Diabetes Mellitus, Type 1 ()

Diabetes Mellitus, Type 2 ()

Endothelial Cells (Phase 4)

Healthy Volunteers (Phase 1)

Hypercholesterolemia (Phase 3)

Hyperglycemia (Phase 4)

Hypertension (Phase 3)

Hypoglycemia (Phase 4)

Metabolic Diseases (Phase 4)

Obesity (Phase 4)

Perinatal Care (Phase 3)

Puerperal Disorders (Phase 3)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 134
  • # of Trial Organizations: 69

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue